ProQR Announces Second Quarter 2026 Operating and Financial Results
ProQR reported Q2 revenue of €8.76 million and narrowed its net loss to €8.7 million, while significantly strengthening its balance sheet. The company closed a $59.2 million financing during the quarter, ending with €117.1 million in cash to support operations into mid-2028. Operationally, ProQR achieved a major milestone by announcing the first clinical validation of its Axiomer RNA editing platform. Positive Phase 1 data for AX-0810 showed an 8-fold increase in serum bile acids, confirming target engagement and supporting further development.
Key figures
- Revenue
- €8.76 million
- Guidance
- Runway extended into mid-2028; multiple clinical data readouts expected through H1 2027
- Runway
- mid-2028
- Net loss
- €8.7 million
- Rd costs
- €12.7 million
- Cash balance
- €117.1 million
- Bile acid increase
- 8-fold
- Financing proceeds
- $59.2 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.